Septerna, Inc. Profit Breakdown
Profit breakdown shows how much each product earned: one column per product, one row per year or quarter. All amounts are the filed figures for that period.
- Septerna, Inc. revenue for the quarter ending 2026-06-30 was $26.75M, a 22375.63% increase year-over-year.
- Septerna, Inc. revenue for the quarter ending 2026-03-31 was $26.52M, a 12010.96% increase year-over-year.
- Septerna, Inc. revenue for the quarter ending 2025-12-31 was $24.12M, a 11276.42% increase year-over-year.
- Septerna, Inc. revenue for the quarter ending 2025-09-30 was $21.5M, a 12113.07% increase year-over-year.
- Septerna, Inc. revenue for fiscal 2025 was $45.95M, a 4174.51% increase from fiscal 2024.
- Septerna, Inc. revenue for fiscal 2024 was $1.08M, a 611.92% increase from fiscal 2023.
- Septerna, Inc. revenue for fiscal 2023 was $151,000.00.
- Available history
- 2023-03-31 to 2026-06-30
- Data captured
Profit by product
Septerna, Inc. did not file profit by product.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |